SWOG clinical trial number
S0029
Single Agent Docetaxel For Metastatic Breast Cancer In Patients Aged 70 Years And Older (And In A Cohort Of Patients Younger Than 60 Years)
Closed
Phase
Accrual
34%
Research committees
Breast Cancer
Treatment
Docetaxel
Eligibility Criteria Expand/Collapse
Women with pathologically confirmed breast cancer; 70 years or older or less than 60 years; measureable disease with distantly metastatic breast cancer (M1 disease); chest x-ray; serum creatinine and bilirubin <= IULN; SGOT/SGPT <= 1.5 x IULN; alkaline phos <= 1.5 x IULN; if there is metastatic disease to the liver, SGOT/SGPT and/or alkaline phos may be up to 2 x IULN; AGC >= 1,500/ul; hemoglobin >= 9gm/dl; platelets >= 100,000/ul; no more than one prior chemotherapy for advanced, recurrent or metastatic disease; pior adjuvant or neoadjuvant therapy OK; prior hormonal therapy OK; prior adjuvant taxanes OK; no know brain or CNS metastases; must have recovered form effects of prior RT or surgery; pharmacokinetic sampling; no known HIV; PS=0,1,2.
Publication Information Expand/Collapse
2016
PMid: PMID27325863 | PMC number: PMC5012713
Other Clinical Trials
SWOG Clinical Trial Number
S2206
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212
TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase